Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. Zilli T, et al. Among authors: everaerts w. Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29. Eur Urol Focus. 2021. PMID: 33386290 Free article. Clinical Trial.
Robot-assisted versus open partial nephrectomy: comparison of outcomes. A systematic review.
Grivas N, Kalampokis N, Larcher A, Tyritzis S, Rha KH, Ficarra V, Buffi N, Ploumidis A, Autorino R, Porpiglia F, van der Poel H, Mottrie A, de Naeyer G; J-ERUS/YAU Robotic Urology Working Group. Grivas N, et al. Minerva Urol Nefrol. 2019 Apr;71(2):113-120. doi: 10.23736/S0393-2249.19.03391-5. Epub 2019 Mar 18. Minerva Urol Nefrol. 2019. PMID: 30895768 Free article.
The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Tosco L, et al. Among authors: everaerts w. Eur Urol Focus. 2018 Apr;4(3):369-375. doi: 10.1016/j.euf.2016.12.008. Epub 2017 Jan 17. Eur Urol Focus. 2018. PMID: 28753838 Clinical Trial.
Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A. Fossati N, et al. Among authors: everaerts w. Eur Urol. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6. Eur Urol. 2019. PMID: 30301694 Free PMC article.
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial.
Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W, Dirix P, Van den Bergh L, Crijns W, Vandendriessche H, Van Wynsberge L, Ost P, Lumen N, Buelens P, Haustermans K, Berghen C, De Meerleer G. Draulans C, et al. Among authors: everaerts w. JMIR Res Protoc. 2018 Dec 13;7(12):e11256. doi: 10.2196/11256. JMIR Res Protoc. 2018. PMID: 30545809 Free PMC article.
Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes.
Devos B, Al Hajj Obeid W, Andrianne C, Diamand R, Peltier A, Everaerts W, Van Poppel H, Van Velthoven R, Joniau S. Devos B, et al. Among authors: everaerts w. World J Urol. 2019 Aug;37(8):1507-1515. doi: 10.1007/s00345-019-02640-x. Epub 2019 Jan 21. World J Urol. 2019. PMID: 30666400
Oligometastatic prostate cancer: The game is afoot.
Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P. Lancia A, et al. Among authors: everaerts w. Cancer Treat Rev. 2019 Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17. Cancer Treat Rev. 2019. PMID: 30684842 Review.
Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, Berghen C, Everaerts W, Albersen M, Tsaturyan A, De Meerleer G, Van Poppel H, Goffin K, Ost P, Tosco L, Joniau S. Battaglia A, et al. Among authors: everaerts w. World J Urol. 2019 Aug;37(8):1543-1549. doi: 10.1007/s00345-019-02716-8. Epub 2019 Mar 12. World J Urol. 2019. PMID: 30859274
110 results